Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593038 | 0.94 | BACE1 (0.48) | BACE1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL592532 | 0.92 | BACE1 (0.48) | BACE1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL592544 | 0.92 | OPRL1 (0.48) | BACE1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL593555 | 0.91 | BACE1 (0.46) | BACE1GAAMAPK1BCHEACHE | |
| SCHEMBL593863 | 0.91 | BACE1 (0.46) | BACE1MAPK1SMN1; SMN2TSHRACHE | |
| SCHEMBL593161 | 0.91 | BACE1 (0.59) | BACE1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL592330 | 0.90 | BACE1 (0.45) | BACE1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL592391 | 0.90 | BACE1 (0.50) | BACE1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL593760 | 0.90 | BACE1 (0.44) | BACE1GAAHRH3MAPK1HTT | |
| SCHEMBL593635 | 0.89 | SIGMAR1 (0.46) | BACE1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804794-B1 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1804794-B1 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2006044497-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | BACE1, BACE2, APP | BACE1 1/4885OPRL1 1765/4885OPRM1 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.